The business of not calling it a cure
A transparency post on the single word our category is legally not allowed to use, the 2023 FDA warning letters that explain why, and the ZBiotics playbook we're quietly borrowing from.
By YOAKE team
There is a single word that will not appear anywhere on yoake.store. Not in our headlines. Not in our product copy. Not in our disclaimers. Not even when we quote other people talking about the category.
You know the word. It's the one a lot of brands in our space lead with. The one that makes FDA lawyers reach for their staplers.
Leaving it out is not a squeamish choice. It is a legal and strategic one. Here is why.
The FDA's position, in one sentence
The FDA treats alcohol intoxication as a disease state. Any product that claims to cure, treat, prevent, or reduce a disease is — legally — a drug, not a supplement. Drugs require FDA approval. Supplements claiming drug-level effects without approval are violating federal law.
In July 2023, the FDA sent warning letters to seven companies selling functional beverages that had been using the word openly in their marketing. The letters demanded the companies cease the drug claims within 15 business days. Several had to pull ad-account access; a few quietly rebranded their lead products. The enforcement was public and fast.
The FTC operates in parallel. In July 2023, the FTC settled with the makers of Sobrenix, a supplement marketed with direct anti-alcohol claims. $650,000 in refunds went back to 536,000 customers. A permanent ban on the specific unsubstantiated claims was part of the consent order.
So the word is not a style preference. It's a regulatory landmine with documented precedent.
What the disciplined brands do instead
ZBiotics, the best-funded and most rigorously-run company in the category, has made its position explicit. Here is their founder Zack Abbott, quoted publicly:
"Our product does not make alcohol safer or better for you. It just enables you to feel better the next day so you can maintain your healthy habits."
That sentence is a masterclass. It avoids every drug claim. It redirects attention to habits, not outcomes. It undersells rather than overpromises. It is also legally bulletproof — an FDA or FTC lawyer reading it cannot build a case on any word in it.
Cheers Health, formerly marketed as a recovery brand in a way that would today be flagged, rebranded as a "liver health" company in 2022 for the same reason. Every word on their website now ladders up to liver support, not alcohol.
The common pattern: structure/function claims, lifestyle framing, no direct alcohol-condition language. Brands that have broken from this pattern have received warning letters, paid restitution, or had their ad accounts terminated. The pattern holds because it works.
What we do
We carry four Japanese functional beverages and supplements that happen to be stocked in every Japanese konbini around the social-drinking occasions they support. We describe what each product is. We translate the Japanese label. We cite the manufacturer and the launch year. We disclose the ingredients.
We do not — anywhere — say that any of these products treats, cures, prevents, or reduces any drinking-related condition. The Japanese manufacturers do not make those claims in Japan. We do not make them in the US.
We also do not use the banned word on our site in any context. Not positively, not negatively, not in disclaimers. It exists in our internal compliance notes; that is the only place it belongs. The search engines that find you when you search for "Japanese liver drink" or "the drink I saw at Lawson" will still connect you to the right page, because those are the terms that actually describe what we sell.
Why we're writing about this publicly
Most DTC brands in a regulatory-adjacent category keep this kind of discipline behind the scenes. They don't write public posts about what they can't say. They just quietly don't say it.
We think writing about it is worth it, for two reasons.
One — it is a trust signal. If you are the kind of customer who cares about rigor, knowing that we have thought through the compliance framework means something. Our entire posture is honesty, and being honest about what we can and cannot claim is part of that.
Two — it is a differentiator. There are still brands in this category saying careless things. The next wave of FDA and FTC enforcement will take some of them out. We would rather you know the constraints we are operating inside than discover them later through a brand's problem.
The constraints are not a bug. They are a shape the serious products in this category share. We are trying to be one of those.